Table 1.
Clinical characteristics in the patients at the start of treatment with an initial oral hypoglycemic agent
| Variable | All cases | Cases matched by propensity score | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Met (n = 1,793) | DPP4i (n = 877) | SU (n = 1,273) | Total (n = 3,943) | P‐value | Met (n = 441) | DPP4i (n = 441) | SU (n = 441) | Total (n = 1,323) | P‐value | |
| Age (years) | 57.1 ± 11.2 | 63.1 ± 11.0 | 62.7 ± 11.1 | 60.3 ± 11.5 | 0.00 | 61.9 ± 10.0 | 62.3 ± 10.8 | 63.7 ± 10.5 | 62.6 ± 10.2 | 0.02 |
| Male (%) | 1,124 (62.6) | 508 (57.9) | 821 (64.4) | 2,453 (62.2) | 0.00 | 272 (61.6) | 267 (60.5) | 279 (63.2) | 818 (61.8) | 0.45 |
| Age‐of‐onset (years) | 51.5 ± 11.3 | 56.7 ± 11.1 | 54.3 ± 12.0 | 53.3 ± 11.6 | 0.00 | 54.5 ± 10.0 | 55.1 ± 11.0 | 55.6 ± 11.7 | 55.1 ± 10.9 | 0.30 |
| Diabetes duration (years) | 5.31 ± 5.69 | 6.61 ± 6.71 | 7.42 ± 8.11 | 6.28 ± 6.85 | 0.00 | 7.63 ± 7.21 | 7.12 ± 5.93 | 7.99 ± 7.48 | 7.49 ± 6.91 | 0.15 |
| Body mass index† | 26.2 ± 4.7 | 23.6 ± 3.6 | 23.6 ± 3.4 | 24.8 ± 4.3 | 0.00 | 24.0 ± 3.4 | 24.0 ± 3.5 | 23.5 ± 3.5 | 23.8 ± 3.5 | 0.03 |
| Systolic BP (mmHg) | 130 ± 16 | 130 ± 16 | 131 ± 17 | 130 ± 16 | 0.38 | 129 ± 15 | 131 ± 16 | 130 ± 16 | 130 ± 16 | 0.22 |
| Diastolic BP (mmHg) | 77.8 ± 11.0 | 78.2 ± 11.3 | 76.9 ± 10.8 | 76.9 ± 11.0 | 0.00 | 75.9 ± 10.2 | 76.8 ± 11.6 | 75.2 ± 10.7 | 76.0 ± 10.9 | 0.09 |
| PPPG (mg/dL) | 179 ± 65 | 163 ± 54 | 194 ± 75 | 180 ± 67 | 0.00 | 175 ± 65 | 166 ± 56 | 176 ± 65 | 172 ± 61 | 0.06 |
| HbA1c (%) | 7.73 ± 1.17 | 7.37 ± 1.00 | 8.07 ± 1.42 | 7.76 ± 1.28 | 0.00 | 7.45 ± 0.96 | 7.52 ± 1.05 | 7.46 ± 1.08 | 7.49 ± 1.03 | 0.68 |
| Total cholesterol (mg/dL) | 200 ± 34 | 196 ± 34 | 203 ± 37 | 201 ± 36 | 0.01 | 201 ± 32 | 196 ± 34 | 194 ± 33 | 196 ± 33 | 0.13 |
| LDL cholesterol (mg/dL) | 118 ± 30 | 108 ± 27 | 117 ± 33 | 116 ± 31 | 0.00 | 113 ± 31 | 110 ± 30 | 112 ± 29 | 111 ± 30 | 0.52 |
| TG (mg/dL) | 194 ± 143 | 152 ± 121 | 168 ± 159 | 176 ± 145 | 0.00 | 188 ± 154 | 159 ± 123 | 147 ± 93 | 164 ± 126 | 0.00 |
BP, blood pressure; DPP4i, dipeptidyl‐peptidase 4 inhibitor; LDL, low‐density lipoprotein; Met, metformin; PPPG, post‐prandial plasma glucose; SU, sulfonylurea; TG triglyceride. Data are mean ± standard deviation. P‐value: variables are compared among the patient groups by one‐way analysis of variance (anova). †The body‐mass index is the weight in kilograms divided by the square of the height in meters.